First Diagnostic Test to Detect Risk of Preterm Birth
Sera Prognostics is a leading women's health company utilizing a proprietary proteomics and bioinformatics platform to discover, develop, and commercialize biomarker tests for major pregnancy-related conditions.
Sera's first commercial product, the PreTRM® Test, is the only broadly validated, commercially available blood-based biomarker test to predict the risk of preterm birth. Results from clinical studies show significant positive effects on the babies’ health, reduced Neonatal Intensive Care Unit stay, and dramatically reduced cost.
Sera also develops a robust pipeline of novel blood-based biomarker tests for a number of additional pregnancy conditions with the aim of significantly improving maternal and neonatal health and dramatically reducing healthcare costs.